ak138d1
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 26, 2025 (NCT06730386)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Receptor tyrosine-protein kinase erbB-3ANTAGONIST
ERBB3 antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07281326 | Phase 1 | Oct 22, 2025 | Akeso Pharmaceuticals, Inc. |
| NCT06730386 | Phase 1 | Feb 26, 2025 | Akeso Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2025 |
1 organizations
Page 1 / 1